Burman Family-controlled entities make insider trading complaint against Religare Chief Saluja

The Burman Family, promoters of Dabur Group and single-largest shareholder in Religare Enterprises Ltd (REL), have approached SEBI accusing REL Chairperson Rashmi Saluja of yet another breach of the market regulator’s insider trading norms.

The Burman Family, promoters of Dabur Group and single-largest shareholder in Religare Enterprises Ltd (REL), have approached SEBI accusing REL Chairperson Rashmi Saluja of yet another breach of the market regulator’s insider trading norms.

The four Burman Family-controlled entities — which had in September 2023 made an open offer to acquire 26 per cent stake in REL— have now alleged that Saluja sold 2.71 million shares worth ₹43 crore between March 26 and 28 this year while possessing crucial price-sensitive information that was not disclosed to the stock exchanges, sources close to the development said.

This was violative of SEBI insider trading prohibition regulations, according to a letter written by these four Burman Family entities to SEBI last month.

Read: Religare Enterprises Board stands firm behind Saluja amid ESOP controversyThis is the second time that Burman Family has accused Saluja of insider trading violations. In November last year, the Burman Family had accused that Saluja as Chairperson of REL had resorted to insider trading of REL shares ahead of open offer announcement in September 2023.

Also read

Burmans in all-out tussle for control of Religare

Corporate tussleIt maybe recalled that REL’s Board led by Saluja and the Burman Family are engaged in a corporate tussle for control of REL. The REL Board under Saluja is resisting Burman Family’s attempts to take control of REL and therefore not in favour of the open offer going through, sources said. Both sides have, over the last nine months, been trading charges at each other for violating insider trading regulations and corporate governance norms. 

In the latest letter to SEBI, the Burman Family is understood to have alleged that Saluja was aware that the REL Board had on March 21, 2024, notified the acquirers (four Burman Family entities) that it had “noticed grave concerns against the Acquirers, their promoters, etc that cast a serious doubt on whether the incoming acquirers (Burman Family) would meet the fit and proper criteria… and there is no occasion for REL to approach the RBI or any other regulator on your behalf”.

This letter of REL Board to acquirers had represented a formal view of the board, which challenged the acquisition of controlling stake in REL by the Burman Family-controlled four entities.

The Burman Family is understood to have conveyed to SEBI that such a conclusion by REL board — although the board is not legally entitled to form such a view and is acting without basis — constitutes “material information” for the purpose of insider trading regulations.

The Burman Family entities have contended in their complaint that if such information had been made public, it would have depressed REL’s share price. They alleged that Saluja had made undue profits from the trade by taking advantage of this information. 

The Burman Family has now urged SEBI to conduct a thorough investigation into the trades undertaken by Saluja and ban Saluja from the securities market, sources said. It had in its earlier complaint to SEBI last year alleged that Saluja sold 1.29 million shares worth ₹34.71 crore on September 21-22, 2023.

This transaction was done by Saluja after a representative of the Burman Family had on September 20 last year informed her of the family’s intention to make an open offer to acquire control of REL, Burman Family had alleged..

Like (0)
Previous May 24, 2024 7:40 pm
Next May 24, 2024 7:42 pm

Related posts

  • Capital Economics warns: AI bubble will burst in 2026

    Capital Economics warns that AI-fueled stock market bubble could burst in 2026

    US Stocks Focus April 29, 2024
  • Tianhong Fund: Net profit in 2023 is 1.408 billion yuan

    On April 25, the 2023 annual report released by Junzheng Group showed that Tianhong Fund achieved operating income of 4.707 billion yuan and net profit of 1.408 billion yuan in 2023. As of the end of 2023, Tianhong Fund\’s total assets were 16.888 billion yuan, a year-on-year increase of 3.91%; net assets were 13.886 billion yuan, a year-on-year increase of 2.87%; Junzheng Group held 15.60% of its equity.

    US Stocks Focus April 25, 2024
  • The State Administration of Financial Supervision responded to netizen suggestions: actively cooperate with the legislative body to conduct research and demonstration on issues such as whether personal bankruptcy should be legalized

    In response to the problem of financing difficulties and expensive financing for private enterprises, the State Administration of Financial Supervision responded: In November 2023, eight departments including the People\’s Bank of China and the State Administration of Financial Supervision issued the \”Notice on Strengthening Financial Support Measures to Support the Development and Growth of the Private Economy\” to continue to increase credit resources. 25 measures were proposed in terms of investment and other aspects. Next, the State Administration of Financial Supervision will strictly implement the requirements of the notice, guide banking financial institutions to continue to improve financial services for private enterprises, urge banking financial institutions to increase support for first loans and credit loans, strengthen technological empowerment, and develop credit suitable for private enterprises. similar financing products and continued to expand the scale of credit loans.

    US Stocks Focus April 25, 2024
  • The vaccine market is turbulent, and Zhifei Biotech’s “big brother” status is difficult to maintain

    For stock trading, please read Jin Qilin analyst research reports. They are authoritative, professional, timely and comprehensive, helping you to tap potential theme opportunities! Source: Financial Investment News Financial Investment News reporter Chen Yuhe After Zhifei Biotechnology (300122), the “vaccine brother”, released its 2023 annual report, its stock price continued to fall. Some market participants attributed its falling stock price to its high reliance on foreign supplies. Business is linked to the gradually revealed decline in performance. In recent years, the vaccine market has been changing. On the one hand, the once \”hot-selling\” nine-price HPV vaccine is no longer hard to find. On the other hand, various good news about the domestically produced nine-price HPV vaccine continue to spread, attracting a lot of attention. Institutions pay great attention to its listing process. Zhifei Bio\’s growth capability indicators Zhi Fei Bio\’s stock price continues to fall. The annual report shows that in 2023, Zhi Fei Bio\’s operating income was 52.918 billion yuan, a year-on-year increase of 38.3%; it achieved net profit attributable to the parent company of 8.07 billion yuan, a…

    US Stocks Focus April 25, 2024
  • Industrial Bank: Net profit fell 3.1% year-on-year in the first quarter

    [Industrial Bank: Net profit in the first quarter fell 3.1% year-on-year] Financial News Agency reported on April 25 that Industrial Bank announced that its net profit in the first quarter was 24.336 billion yuan, a year-on-year decrease of 3.1%.

    US Stocks Focus April 25, 2024
  • Graphic | 1994 vs. 10 U.S. companies with the highest revenue in 2023

    Gelonghui May 20 | Since the 1990s, the business field has undergone tremendous changes

    US Stocks Focus May 20, 2024